-
STUDY17022
First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Study Information
-
STUDY20051
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High Risk Pancreatic Neuroendocrine Tumors
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
Study Information
-
STUDY21781
A Phase 1 Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels
To refine the dose and schedule of AV-380 and establish its adverse event (AE),
pharmacokinetic (PK), and pharmacodynamic (PD) profile in metastatic cancer patients with
cachexia and elevated GDF-15, receiving SoC chemotherapy for metastatic cancer
Study Information
-
STUDY23847
Phase II Study Evaluating NALIRIFOX versus Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients with Locally Advanced and Metastatic Pancreatic Adenocarcinoma
Compare the anti-tumor activity of the NALIRIFOX and mGAP regimens in patients with locally advanced, unresectable, and metastatic PDAC. To assess the safety of the NALIRIFOX and mGAP regimens in patients with locally advanced, unresectable, and metastatic PDAC. To evaluate the anti-tumor activity of the NALIRIFOX and mGAP regimens in patients with locally advanced, unresectable, and metastatic PDAC.
Study Information
-
STUDY23849
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a study. Phase 1 adopts an accelerated titration at first dose level followed with classic "3+3" design to identify the MTD and/or RP2D. Phase 2a is a dose expansion phase to confirm the safety, tolerability and explore efficacy in selected malignant solid tumors treated with DB-1311 as monotherapy.
Study Information